What were Lupin Ltd's latest quarterly results?
Lupin Ltd's latest quarterly results (Mar 2026) show
- PAT Growth YoY: +87.9%
- Revenue Growth YoY: +31.9%
- Operating Margin: 33.0%
Lupin Ltd (Pharma - Formulators) — fundamental analysis, earnings data, and key metrics. PE: 18.6. ROE: 29.1%. This stock is not currently in the Nifty 500 momentum outperformers list.
Based on publicly available financial data. This is educational research, not investment advice.
Lupin Ltd's latest quarterly results (Mar 2026) show
Lupin Ltd's current PE ratio is 18.6x.
Lupin Ltd's price-to-book ratio is 4.8x.
Lupin Ltd's fundamental strength based on key financial ratios
Lupin Ltd has a debt-to-equity ratio of N/A.
Lupin Ltd's return ratios over recent years
Lupin Ltd's operating cash flow is positive (FY2026).
Lupin Ltd's current dividend yield is 0.51%.
Lupin Ltd's shareholding pattern (Mar 2026)
Lupin Ltd's promoter holding has decreased recently.
Lupin Ltd is an established outperformer with 1 weeks of consecutive Nifty 500 outperformance.
Based on quantitative research signals, here is why Lupin Ltd may be worth studying
Lupin Ltd investment thesis summary:
Lupin Ltd's forward outlook based on current data signals
The above FAQs are generated from publicly available earnings data and conference call transcripts. This is educational research only. Sector Alpha is not SEBI registered and does not provide investment advice.